ACORN CAPITAL ADVISORS, LLC
Long book
$351.8M
Q1 2026
Positions
22
Top-10 weight
89%
concentration
Last quarter
+34.1%
SPY +14.8%
Turnover
13%
of book per quarter
Strategy in plain words
auto-generated from filingsACORN CAPITAL ADVISORS, LLC is a concentrated fundamental stock-picker, specialised in healthcare (100% of the long book), running a $351.8M US long book across 22 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. Turnover is modest: positions are typically held for years. Current anchor positions: TERNS PHARMACEUTICALS INC, CG ONCOLOGY INC, UROGEN PHARMA LTD, PUMA BIOTECHNOLOGY INC, TREVI THERAPEUTICS INC.
Over the last 6 quarters its long book ran on average 6.9pp per quarter ahead of the S&P 500, beating the index in 4 of 6 quarters. We rate its filings highest-signal: new buys here are worth attention.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q4 2024
-19.8%
Q1 2025
-2.4%
Q2 2025
+38.0%
Q3 2025
+12.4%
Q4 2025
+6.7%
Q1 2026
+34.1%
Sector allocation
Healthcare 74%
Other 26%
Long book by quarter
What does ACORN CAPITAL own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| 430 TERNS PHARMACEUTICALS INC | — | 1.7M | $92.1M | 26.2% | Held |
| CGON CG ONCOLOGY INC | Healthcare | 1.1M | $76.6M | 21.8% | -0.1% |
| URGN UROGEN PHARMA LTD | Healthcare | 1.7M | $30.1M | 8.6% | +15.5% |
| PBYI PUMA BIOTECHNOLOGY INC | Healthcare | 4.1M | $26.4M | 7.5% | Held |
| TRVI TREVI THERAPEUTICS INC | Healthcare | 2.1M | $25.6M | 7.3% | Held |
| CADL CANDEL THERAPEUTICS INC | Healthcare | 3.5M | $17.2M | 4.9% | +35.6% |
| BCAX BICARA THERAPEUTICS INC | Healthcare | 643.4K | $12.8M | 3.6% | Held |
| OKUR ONKURE THERAPEUTICS INC-A | Healthcare | 2.8M | $11.8M | 3.3% | Held |
| JBIO JADE BIOSCIENCES INC | Healthcare | 786.8K | $11.1M | 3.1% | New |
| TARA PROTARA THERAPEUTIC INC | Healthcare | 1.8M | $9.1M | 2.6% | Held |
| VSTM VERASTEM INC | Healthcare | 1.5M | $7.8M | 2.2% | Held |
| HELP CYBIN INC | Healthcare | 1.5M | $7.4M | 2.1% | -2.1% |
| LONA LEONABIO INC | Healthcare | 634.5K | $6.5M | 1.9% | +26.5% |
| AURA AURA BIOSCIENCES INC | Healthcare | 595.7K | $4.0M | 1.1% | Held |
| WHWK WHITEHAWK THERAPEUTICS INC | Healthcare | 1.1M | $3.9M | 1.1% | Held |
| CRDF CARDIFF ONCOLOGY INC | Healthcare | 1.8M | $2.9M | 0.8% | -10.2% |
| QTTB Q32 BIO INC | Healthcare | 315.1K | $2.0M | 0.6% | -36.1% |
| KPTI KARYOPHARM THERAPEUTICS INC | Healthcare | 287.8K | $1.6M | 0.5% | New |
| JSPR JASPER THERAPEUTICS INC | Healthcare | 1.4M | $1.2M | 0.4% | -21.0% |
| XFOR X4 PHARMACEUTICALS INC | Healthcare | 234.0K | $967K | 0.3% | -14.4% |
| BCAB BIOATLA INC | Healthcare | 5.4M | $865K | 0.2% | +11.8% |
| VYNE VYNE THERAPEUTICS INC | Healthcare | 1.4K | $855 | 0.0% | Held |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 15, 2026 | 22 | $351.8M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 17, 2026 | 21 | $295.1M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 17, 2025 | 20 | $197.0M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 21 | $152.9M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR/ARESTATEMENT | May 19, 2025 | 22 | $149.9M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 22 | $143.7M | SEC ↗ | |
| Q4 2024 | 13F-HR/ARESTATEMENT | May 19, 2025 | 21 | $185.8M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR/ANEW HOLDINGS | May 7, 2025 | 21 | $190.5M | SEC ↗ | |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 20 | $185.0M | SEC ↗ |